Serum High-Density Lipoprotein Cholesterol and Breast Cancer Risk by Menopausal Status, Body Mass Index, and Hormonal Receptor in Korea

High-density lipoprotein cholesterol (HDL-C) has been suggested to be associated with breast cancer. However, the roles of HDL-C and hypertriglyceridemia on breast cancer still have been controversial. The goal of this study was to investigate the association between HDL-C with breast cancer risk, stratifying by menopausal status, and body mass index. The hormonal receptor status of breast has been proposed to modify the effect of HDL-C on breast cancer. Multicenter hospital-based case-control study was conducted from November 2004 to December 2005 in Korea. After one to two individual matchings by age (+/- 5 years) and menopausal status, 690 cases and 1,380 controls were included in the analysis. Odds ratios (OR) and 95% confidence intervals (95% Cl) were estimated by conditional, unconditional, and multinomial logistic regressions. Protective effect of HDL-C on breast cancer was only observed among premenopausal women with an OR (95% Cl) of 0.49 (0.33-0.72) for HDL-C >= 60 versus = 150 mg/dL) category was 2.20 (1.32-3.67) on estrogen receptor-negative and progesterone receptor-negative breast cancer compared with high HDL-C (>= 50 mg/dL) and low TG (< 150 mg/dL) category. This study suggests that higher level of HDL-C may reduce breast cancer risk among premenopausal women. Estrogen receptor-negative and progesterone receptor-negative breast cancer was associated with dyslipidemia, which implicates that association among HDL-C, TG, and breast cancer may be modified by receptor status. (Cancer Epidemiol Biomarkers Prev 2009;18(2):508-15)Kucharska-Newton AM, 2008, ANN EPIDEMIOL, V18, P671, DOI 10.1016/j.annepidem.2008.06.006Song YM, 2008, J CLIN ONCOL, V26, P3395, DOI 10.1200/JCO.2007.15.7867Kim Y, 2007, EUR J CANCER PREV, V16, P124Browning DRL, 2007, INT J CANCER, V120, P833, DOI 10.1002/ijc.22366Canoy D, 2006, ATHEROSCLEROSIS, V189, P420, DOI 10.1016/j.atherosclerosis.2005.12.027Bonovas S, 2006, J CLIN ONCOL, V24, P4808, DOI 10.1200/JCO.2006.06.3560Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061Renehan AG, 2006, ENDOCR-RELAT CANCER, V13, P273, DOI 10.1677/erc.1.01219Kumar AS, 2006, J CLIN ONCOL, V24, P2127, DOI 10.1200/JCO.2005.04.9882Rollison DE, 2006, INT J CANCER, V118, P1279, DOI 10.1002/ijc.21471YOO KY, 2006, ASIAN PAC J CANCER P, V7, P679Ferretti G, 2006, ATHEROSCLEROSIS, V184, P1, DOI 10.1016/j.atherosclerosis.2005.08.008Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751Bahl M, 2005, BREAST CANCER RES TR, V94, P135, DOI 10.1007/s10549-005-6654-9Eliassen AH, 2005, ARCH INTERN MED, V165, P2264, DOI 10.1001/archinte.165.19.2264Furberg AS, 2005, CANCER EPIDEM BIOMAR, V14, P33Michalaki V, 2005, MOL CELL BIOCHEM, V268, P19Johansson H, 2004, BREAST CANCER RES TR, V88, P63Furberg AS, 2004, J NATL CANCER I, V96, P1152, DOI 10.1093/jnci/djh216Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535Renehan AG, 2004, LANCET, V363, P1346Malin A, 2004, CANCER, V100, P694, DOI 10.1002/cncr.20023Cao WM, 2004, CANCER RES, V64, P1515FERLAY J, 2004, GLOBOCAN 2002 CANC IBray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932WEIDERPASS E, 2004, CANCER EPIDEM BIOMAR, V13, P112Haddy N, 2003, ATHEROSCLEROSIS, V170, P277, DOI 10.1016/S0021-9150(03)00287-9Holland NT, 2003, MUTAT RES-REV MUTAT, V543, P217Stephenson GD, 2003, NUTR CANCER, V45, P1, DOI 10.1207/S15327914NC4501_1Hsing AW, 2003, J NATL CANCER I, V95, P67, DOI 10.1093/jnci/95.1.67Lee JP, 2002, IEEE COMPUT GRAPH, V22, P6, DOI 10.1109/MCG.2002.1028720Dorgan JF, 2002, J NATL CANCER I, V94, P606Yoo KY, 2002, J KOREAN MED SCI, V17, P1Sanderson M, 2002, BRIT J CANCER, V86, P84, DOI 10.1038/sj/bjc.6600009*NAT CHOL ED PROGR, 2002, CIRCULATION, V106, P3143Farina HG, 2002, CLIN EXP METASTAS, V19, P551BURGER D, 2002, AUTOIMMUN REV, V1, P111Ray G, 2001, CLIN BIOCHEM, V34, P71, DOI 10.1016/S0009-9120(00)00200-9Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514Moorman PG, 1998, CANCER EPIDEM BIOMAR, V7, P483Agurs-Collins T, 1998, J CANCER RES CLIN, V124, P186GAARD M, 1994, CANCER CAUSE CONTROL, V5, P501KRONENBERG F, 1994, J LIPID RES, V35, P1318FERRARONI M, 1993, INT J EPIDEMIOL, V22, P772PIKE MC, 1993, EPIDEMIOL REV, V15, P17HOYER AP, 1992, CANCER CAUSE CONTROL, V3, P403BOYD NF, 1990, J NATL CANCER I, V82, P460ROTHENEDER M, 1989, INT J CANCER, V43, P875